Valuation: Vericel Corporation

Market Cap 2.05B 1.79B 1.69B 1.53B 2.87B 197B 2.88B 20.21B 7.8B 99.97B 7.7B 7.53B 322B P/E 2026 *
72.4x
P/E 2027 * 45.5x
Enterprise Value 2.05B 1.79B 1.69B 1.53B 2.87B 197B 2.88B 20.21B 7.8B 99.97B 7.7B 7.53B 322B EV / Sales 2026 *
6.1x
EV / Sales 2027 * 5.22x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day-0.02%
1 week+4.38%
Current month+0.30%
1 month-9.58%
3 months-0.20%
6 months+23.90%
Current year+11.14%
1 week 38.2
Extreme 38.2
40.87
1 month 37.35
Extreme 37.35
43.48
Current year 28.95
Extreme 28.95
49.32
1 year 28.95
Extreme 28.95
49.32
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 2013-02-28
Director of Finance/CFO 51 2021-01-24
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 71 2005-09-27
Chairman 75 2012-10-04
Director/Board Member 57 2013-08-22
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Exercice

Director

21,000 0.0411%
8/3/26 Exercice

Chief Operating Officer

30,000 0.0587%
7/30/26 Exercice

Controller/Auditor

13,500 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%+4.38%+25.65%+17.88% 2.05B
-0.58%+0.43%+31.09%-4.81% 78.83B
-1.11%+3.59%-12.67%-34.40% 60.48B
-2.55%+6.99%+505.27%+47.92% 63.11B
+0.14%-1.76%-10.86%+24.38% 46.75B
-0.24%+1.22%+2.26%+151.03% 45.66B
-1.62%-0.76%+49.85%-14.92% 32.37B
-1.81%+3.16%+45.71%+110.57% 25.87B
+0.47%+2.38%+0.10%+146.43% 21.33B
+0.27%+1.87%+63.02%+99.38% 15.8B
Average -0.71%+3.63%+69.94%+54.34% 39.22B
Weighted average by Cap. -0.93%+3.95%+94.36%+40.05%

Financials

2026 *2027 *
Net sales 336M 293M 277M 251M 471M 32.26B 473M 3.32B 1.28B 16.4B 1.26B 1.23B 52.78B 393M 343M 324M 294M 550M 37.7B 553M 3.88B 1.5B 19.17B 1.48B 1.44B 61.68B
Net income 29.29M 25.54M 24.12M 21.9M 41.03M 2.81B 41.2M 289M 111M 1.43B 110M 108M 4.6B 47.29M 41.24M 38.94M 35.36M 66.24M 4.54B 66.52M 466M 180M 2.31B 178M 174M 7.42B
Net Debt - -
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
26-09-18 US$40.02 -0.02% 1,121,973
26-09-17 US$40.03 -0.45% 536,421
26-09-16 US$40.21 +1.23% 490,484
26-09-15 US$39.72 +0.30% 654,831
26-09-14 US$39.60 +3.29% 629,429
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
40.02USD
Average target price
60.57USD
Spread / Average Target
+51.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VCEL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!